Avacta Group plc (GB:AVCT) has released an update.
Avacta Group plc has announced the successful completion of the second cohort in the Phase 1 trial of AVA6000, a promising cancer treatment, with dosing underway for the third cohort. With a strong cash position, the company is positioned to advance AVA6000 into Phase 2 trials and further develop its innovative medicine pipeline. Additionally, Avacta has bolstered its leadership with the appointment of Darlene Deptula-Hicks as Non-Executive Director, enhancing its strategic and commercial expertise.
For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.
